

**OFFICIAL**

11/10/97

PATENT  
DOCKET NO. 329368-101A  
SERIAL NO. 08/854,825

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chisari et al.  
Serial No.: 08/854,825  
Filing Date: May 12, 1997  
For: PEPTIDES FOR INDUCING CYTOTOXIC T  
LYMPHOCYTE RESPONSES TO HEPATITIS C VIRUS  
Docket No.: 329368-101A (as amended hereby)

Art Unit: 1813  
Examiner: Parkin

Jan 1/2/07

Assistant Commissioner for Patents  
Washington, DC 20231

**PRELIMINARY AMENDMENT**

Dear Sir:

This Amendment is being submitted for the purpose of directing the examination of the present continuation application to new claims that were not considered in the previously allowed parent case, namely Serial No. 08/214,650. Applicants respectfully request that the following amendments be entered and that the pending claims of the instant patent application be considered in view of the discussion provided herein.

**IN THE DOCKET NUMBER:**

Please strike the docket number of this case as filed, i.e., "329368-101CON", and substitute therefor -- 329368-101A --.

**IN THE TITLE:**

Please strike the title of this case as filed, i.e., "PEPTIDES FOR INDUCING CYTOTOXIC T LYMPHOCYTE RESPONSES TO HEPATITIS C VIRUS", and substitute therefor -- HEPATITIS C VIRUS-DERIVED PEPTIDES CAPABLE OF INDUCING CYTOTOXIC T LYMPHOCYTE RESPONSES --.

**IN THE SPECIFICATION:** (R)

At page 1, line 3, strike "grants", and substitute therefor -- Grant No. AI20001 --.


---

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office Fax No. (703) 305-7939 on November 10, 1997.

Typed or printed name of person signing this certificate:

Donald J. Silver

Signature:



TFW sent you 1/2/07

2

**PATENT**  
**DOCKET NO. 329368-101A**  
**SERIAL NO. 08/854,825**

~~At page 6, lines 26-27, strike "SEQ ID NO:55" and substitute therefor -- E1<sub>257-266</sub>; SEQ ID NO:3--.~~

At page 8, line 36, strike "SEQ ID NO:55" and substitute therefor -- E1<sub>257-266</sub>; SEQ ID NO:3 --.

At page 9, line 26, after "acids", insert -- or to less than about 50 amino acids --.

At page 11, line 14, strike "arylalkyl" and substitute therefor -- aralkyl --.

At page 16, line 17, strike "SEQ ID NO:55" and substitute therefor -- E1<sub>257-266</sub>; SEQ ID NO:3 --.

**At page 26, line 17, strike "HBV", and substitute therefor -- HCV --.**

~~At page 36, lines 7-8, strike "tripalmitoyl-S-glycerylcysteinly-seryl-serine" and substitute therefor -- tripalmitoyl-S-glycerylcysteinyl-seryl-serine --.~~

**At page 36, line 36, strike “•1985” and substitute therefor -- 1985 --**

**At page 38, line 31, strike "injection" and substitute therefor-- injection --.**

At page 39, line 21, strike "SEQ ID NO:55" and substitute therefor -- E1<sub>257-266</sub>; SEQ ID NO:3 --.

At page 39, line 28, strike "neucleocapside-encoded" and substitute therefor  
-- nucleocapsid-encoded --

At page 44, line 9, strike "stimulation. Falk" and substitute therefor -- stimulation, as described by Falk --. (ncc)

~~At page 46, line 15, strike the line.~~

At page 49, line 10, strike "Ma" and substitute therefor -- MA --.

At page 58, line 7, strike "activity (is" and substitute therefor -- activity is (is)

At page 59, line 6, strike "Aichele," and substitute therefor -- Aichele (f.s.c.)

## IN THE CLAIMS:

**Please cancel all currently pending claims, namely claims 10-19 and 21, without prejudice.**

**Please add the following claims:**

22. An isolated peptide that induces an hepatitis C virus (HCV)-specific response in cytotoxic T lymphocytes having a sequence that differs no more than about 20% from ADLMGYIPLV (Core<sub>131-140</sub>; SEQ ID NO:1), DLMGYIPLV (Core<sub>132-140</sub>; SEQ ID NO:54), LLALLSCLTV (Core<sub>178-187</sub>; SEQ ID NO:2), QLRRHIDLLV (E1<sub>257-266</sub>; SEQ ID NO:3), LLCPAGHAV (NS3<sub>1169-1177</sub>; SEQ ID NO:26), KLVALGINAV (NS3<sub>1406-1415</sub>; SEQ ID NO:45).